Literature DB >> 16738983

Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients.

K Arapis1, R Caliandro, J-B Stern, P Girard, D Debrosse, D Gossot.   

Abstract

BACKGROUND: The aim of this study was to analyze the results of pleurodesis for malignant pleural effusion performed by surgeons. PATIENTS AND METHODS: A series of 273 patients with malignant pleural effusion underwent thoracoscopy with the aim of performing a palliative pleurodesis. There were 94 males (34.4%) and 175 females (64.1%), ranging in age from 15 to 94 years (mean age: 60.6 years). The effusion was on the right side in 136 patients (49.8%), on the left side in 110 (40.3%), and bilateral in 27 (9.9%). Thoracoscopy was performed under general anaesthesia in all patients. Pleural biopsy was performed in two thirds of the patients (70.7%). Pleurodesis was produced by instillation of 5g of sterile asbestos-free talc; the chest tube was left in place a minimum of 3 days. It was removed when fluid drainage was less than 200 ml/24 h. Patients were usually discharged the day after chest tube removal.
RESULTS: There was no intraoperative mortality. Two patients (0.7%) had intraoperative complications; 17 (6.2%) underwent a bilateral pleurodesis, and 10 (3.7%) had a pericardiopleural window. In 32 patients (11.7%) no pleurodesis was done, either because the lung did not properly re-expand (5.2%), or because of suspected infection, e.g., false membranes (1.9%), or because of multiple adhesions (4.6%). Finally, only 241 patients (88.3%) had a talc poudrage at the time of thoracoscopy. Duration of postoperative pleural drainage ranged between 1 and 11 days (mean: 3.64 days). The postoperative hospital stay ranged from 2 to 21 days (mean: 7.1 days). Pleural empyema occurred in 4 patients (1.5%) and was lethal in one patient. The mean follow-up period was 8.39 (7.2 months, and 172 patients had regular follow up. In this group, there were 24 recurrences (14%), 12 of which were treated by repeat pleurodesis. The results were very good in 133 patients (77.3%), acceptable in 35 patients (20.3%), and there was a failure in 4 patients (2.4%).
CONCLUSIONS: Results of surgical thoracoscopy for malignant pleural effusion are good, with low morbidity. However, in debilitated patients, bedside talc slurry may be preferable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16738983     DOI: 10.1007/s00464-005-0534-6

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  18 in total

1.  Serious complications with talc slurry pleurodesis.

Authors:  A Brant; T Eaton
Journal:  Respirology       Date:  2001-09       Impact factor: 6.424

2.  Thoracoscopic decortication: a role for video-assisted surgery in chronic postpneumonic pleural empyema.

Authors:  D A Waller; A Rengarajan
Journal:  Ann Thorac Surg       Date:  2001-06       Impact factor: 4.330

3.  Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions.

Authors:  G Cardillo; F Facciolo; L Carbone; M Regal; F Corzani; A Ricci; M Di Martino; M Martelli
Journal:  Eur J Cardiothorac Surg       Date:  2002-02       Impact factor: 4.191

4.  Thoracoscopic pleurodesis with minocycline vs talc in the porcine model.

Authors:  C B Whitlow; R Craig; K Brady; S P Hetz
Journal:  Surg Endosc       Date:  1996-11       Impact factor: 4.584

5.  Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients.

Authors:  M Schulze; A S Boehle; R Kurdow; P Dohrmann; D Henne-Bruns
Journal:  Ann Thorac Surg       Date:  2001-06       Impact factor: 4.330

6.  Primary treatment of malignant pleural effusions: video-assisted thoracoscopic surgery poudrage versus tube thoracostomy.

Authors:  Kurt V Erickson; Michael Yost; Raymond Bynoe; Carl Almond; James Nottingham
Journal:  Am Surg       Date:  2002-11       Impact factor: 0.688

7.  Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion.

Authors:  A P Yim; A T Chan; T W Lee; I Y Wan; J K Ho
Journal:  Ann Thorac Surg       Date:  1996-12       Impact factor: 4.330

8.  Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial.

Authors:  Fabio José Haddad; Riad Naim Younes; Jefferson Luiz Gross; Daniel Deheinzelin
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

9.  Early and late mortality after pleurodesis for malignant pleural effusion.

Authors:  Alain Bernard; Régis Bernard de Dompsure; Olivier Hagry; Jean Pierre Favre
Journal:  Ann Thorac Surg       Date:  2002-07       Impact factor: 4.330

10.  Minimally invasive thoracic surgery for diagnostic assessment and palliative treatment in recurrent neoplastic pleural effusion.

Authors:  P P Brega-Massone; B Conti; B Magnani; F Ferro; C Lequaglie
Journal:  Thorac Cardiovasc Surg       Date:  2004-08       Impact factor: 1.827

View more
  10 in total

1.  Mesothelioma: a review.

Authors:  Frank E Mott
Journal:  Ochsner J       Date:  2012

2.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

3.  Simple technique of talc delivery for video-assisted talc pleurodesis.

Authors:  Rajwinder S Jutley; Salman Waqar; Neil Raha; Paul Fenton; Pradip K Sarkar
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-02-12

Review 4.  Pleural controversies: indwelling pleural catheter vs. pleurodesis for malignant pleural effusions.

Authors:  Marc Fortin; Alain Tremblay
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 5.  Interventional pulmonologist perspective: treatment of malignant pleural effusion.

Authors:  Andrew J Sweatt; Arthur Sung
Journal:  Curr Treat Options Oncol       Date:  2014-12

6.  Treatment of malignant pleural effusion: a cost-effectiveness analysis.

Authors:  Varun Puri; Tanya L Pyrdeck; Traves D Crabtree; Daniel Kreisel; Alexander S Krupnick; Graham A Colditz; G Alexander Patterson; Bryan F Meyers
Journal:  Ann Thorac Surg       Date:  2012-05-10       Impact factor: 4.330

Review 7.  Surgical and other invasive approaches to recurrent pleural effusion with malignant etiology.

Authors:  Siyamek Neragi-Miandoab
Journal:  Support Care Cancer       Date:  2008-02-08       Impact factor: 3.603

Review 8.  Management of malignant pleural effusion: challenges and solutions.

Authors:  Erika Penz; Kristina N Watt; Christopher A Hergott; Najib M Rahman; Ioannis Psallidas
Journal:  Cancer Manag Res       Date:  2017-06-23       Impact factor: 3.989

Review 9.  Complications of thoracoscopic talc insufflation for the treatment of malignant pleural effusions: a meta-analysis.

Authors:  Wen Zhang; Yun-Long Zhao; Shao-Jun Li; Ying-Nan Zhao; Nan-Nan Guo; Bo Liu
Journal:  J Cardiothorac Surg       Date:  2021-05-04       Impact factor: 1.637

10.  Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion.

Authors:  Deirdre B Fitzgerald; Calvin Sidhu; Charley Budgeon; Ai Ling Tan; Catherine A Read; Benjamin C H Kwan; Nicola Ann Smith; Edward T Fysh; Sanjeevan Muruganandan; Tajalli Saghaie; Ranjan Shrestha; Arash Badiei; Phan Nguyen; Andrew Burke; John Goddard; Morgan Windsor; Julie McDonald; Gavin Wright; Kasia Czarnecka; Parthipan Sivakumar; Kazuhiro Yasufuku; David J Feller-Kopman; Nick A Maskell; Kevin Murray; Y C Gary Lee
Journal:  Trials       Date:  2022-06-27       Impact factor: 2.728

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.